文献速递癫痫

拉考沙胺辅助治疗儿童局灶性癫痫的疗效与耐受性

Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures.
PubMed 文献 · Neurology · 2019-08-28

结果显示拉考沙胺组每28天局灶性发作频率较基线降低31.7%(p=0.0003),50%应答率52.9%高于安慰剂组33.3%(OR 2.17,p=0.0006)。常见不良事件为嗜睡和头晕,整体耐受性良好。

要点

  • 拉考沙胺辅助治疗可显著降低4至17岁患者局灶性发作频率。
  • 维持期拉考沙胺组发作频率中位降低51.7%,安慰剂组为21.7%。
  • 常见不良事件为嗜睡(14.0%)和头晕(10.5%),总体耐受性良好。

核心结论

  • 拉考沙胺辅助治疗对4至17岁未控制局灶性癫痫患者有效,且总体耐受性良好。

研究设计与样本

  • 经6周滴定期达到目标剂量后进入10周维持期,主要终点为每28天局灶性发作频率自基线的变化。

主要发现

  • 拉考沙胺组(n=170)每28天局灶性发作频率较基线降低31.7%,安慰剂组(n=168)降低幅度未报告,组间差异p=0.0003。
  • 维持期拉考沙胺组每28天局灶性发作频率中位降低51.7%,安慰剂组为21.7%。
  • 50%应答率(发作减少≥50%)拉考沙胺组为52.9%,安慰剂组为33.3%(OR 2.17,p=0.0006)。
  • 治疗期间不良事件发生率拉考沙胺组67.8%,安慰剂组58.1%;最常见(≥10%)为嗜睡(14.0% vs 5.2%)和头晕(10.5% vs 3.5%)。
  • 因不良事件终止治疗的比例拉考沙胺组4.1%,安慰剂组5.8%。

关键数值与推荐

  • 目标剂量范围:体重<30 kg者口服溶液8-12 mg/kg/d;≥30-<50 kg者口服溶液6-8 mg/kg/d;≥50 kg者片剂300-400 mg/d。
  • 该试验提供I级证据表明拉考沙胺辅助治疗可减少儿童和青少年未控制局灶性发作的频率。

临床怎么用

  • 对于4至17岁未控制局灶性癫痫患者,可考虑拉考沙胺作为辅助治疗以降低发作频率。
  • 用药时需关注嗜睡和头晕等常见不良事件,并根据体重选择相应剂型和剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal (partial-onset) seizures. METHODS: In this double-blind trial (SP0969; NCT01921205), patients (age ≥4-<17 years) with uncontrolled focal seizures were randomized (1:1) to adjunctive lacosamide/placebo. After a 6-week titration, patients who reached the target dose range for their weight (<30 kg: 8-12 mg/kg/d oral solution; ≥30-<50 kg: 6-8 mg/kg/d oral solution; ≥50 kg: 300-400 mg/d tablets) entered a 10-week maintenance period. The primary outcome was change in focal seizure frequency per 28 days from baseline to maintenance. RESULTS: Three hundred forty-three patients were randomized; 306 (lacosamide 152 of 171 [88.9%]; placebo 154 of 172 [89.5%]) completed treatment (titration and maintenance). Adverse events (AEs) were the most common reasons for discontinuation during treatment (lacosamide 4.1%; placebo 5.8%). From baseline to maintenance, percent reduction in focal seizure frequency per 28 days for lacosamide (n = 170) vs placebo (n = 168) was 31.7% (p = 0.0003). During maintenance, median percent reduction in focal seizure frequency per 28 days was 51.7% for lacosamide and 21.7% for placebo. Fifty percent responder rates (≥50% reduction) were 52.9% and 33.3% (odds ratio 2.17, p = 0.0006). During treatment, treatment-emergent AEs were reported by 67.8% lacosamide-treated patients (placebo 58.1%), most commonly (≥10%) somnolence (14.0%, placebo 5.2%) and dizziness (10.5%, placebo 3.5%). CONCLUSIONS: Adjunctive lacosamide was efficacious in reducing seizure frequency and generally well tolerated in patients (age ≥4-<17 years) with focal seizures. CLINICALTRIALSGOV IDENTIFIER: NCT01921205. CLASSIFICATION OF EVIDENCE: This trial provides Class I evidence that for children and adolescents with uncontrolled focal seizures, adjunctive lacosamide reduces seizure frequency.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology. 2019. PMID: 31462582. doi:10.1212/WNL.0000000000008126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。